Regular Insulin vs Rapid Insulin Delivered by V-Go
Efficacy and Safety Comparison Between U-100 Regular Human Insulin and Rapid Acting Insulin When Delivered by VGo Wearable Insulin Delivery in Type 2 Diabetes
Sponsor: Dallas Diabetes Research
Listed as NCT03495908, this NA trial focuses on Type 2 Diabetes and Type 2 Diabetes Mellitus and remains completed. Sponsored by Dallas Diabetes Research, it has been updated 11 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Feb 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Feb 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Apr 2021 — Jul 2024 [monthly]
Completed NA
-
Feb 2021 — Apr 2021 [monthly]
Completed NA
▶ Show 6 earlier versions
-
Jan 2021 — Feb 2021 [monthly]
Completed NA
-
Feb 2020 — Jan 2021 [monthly]
Completed NA
-
Sep 2019 — Feb 2020 [monthly]
Completed NA
Status: Recruiting → Completed
-
Mar 2019 — Sep 2019 [monthly]
Recruiting NA
-
Jun 2018 — Mar 2019 [monthly]
Recruiting NA
-
May 2018 — Jun 2018 [monthly]
Recruiting NA
First recorded
Apr 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Dallas Diabetes Research
- East Coast Institute for Research
- Valeritas, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .